Search hospitals > California > San Francisco
San Francisco General Hospital
Claim this profileSan Francisco, California 94110
Global Leader in Human Immunodeficiency Virus Infection
Global Leader in HIV/AIDS
Conducts research for Cancer
Conducts research for Infections
Conducts research for Breast Cancer
258 reported clinical trials
46 medical researchers
Summary
San Francisco General Hospital is a medical facility located in San Francisco, California. This center is recognized for care of Human Immunodeficiency Virus Infection, HIV/AIDS, Cancer, Infections, Breast Cancer and other specialties. San Francisco General Hospital is involved with conducting 258 clinical trials across 327 conditions. There are 46 research doctors associated with this hospital, such as Hope Rugo, MD, Steven J Deeks, MD, Chia-Ching (Jackie) Wang, and Lee-may Chen, MD.Area of expertise
1Human Immunodeficiency Virus Infection
Global Leader2HIV/AIDS
Global LeaderStage IV
Stage III
CD4+ cell count positive
Top PIs
Hope Rugo, MDUniversity of California San Francisco4 years of reported clinical research
Expert in Breast Cancer
Studies Cancer
19 reported clinical trials
45 drugs studied
Steven J Deeks, MDSan Francisco General Hospital2 years of reported clinical research
Studies Human Immunodeficiency Virus Infection
Studies Coronavirus
11 reported clinical trials
14 drugs studied
Chia-Ching (Jackie) WangZuckerberg San Francisco General Hospital2 years of reported clinical research
Studies HIV/AIDS
Studies Kaposi's Sarcoma
5 reported clinical trials
11 drugs studied
Lee-may Chen, MDUCSF Medical Center-Mission Bay3 years of reported clinical research
Studies Serous Cystadenocarcinoma
Studies Cancer
6 reported clinical trials
11 drugs studied
Clinical Trials running at San Francisco General Hospital
Breast Cancer
Cancer
Colorectal Cancer
Heart Failure
Anal Cancer
Cardiac Arrest
Rectal Cancer
Coronavirus
Human Immunodeficiency Virus Infection
HIV/AIDS
Imlunestrant
for Early Breast Cancer
This trial is testing a new medication called imlunestrant to see if it works better than standard hormone treatments for certain breast cancer patients. The study focuses on patients with early-stage breast cancer that is estrogen receptor positive and HER2 negative, who have already been on hormone therapy for a period of time and are at high risk of their cancer returning. Imlunestrant works by blocking estrogen from helping cancer cells grow.
Recruiting2 awards Phase 36 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at San Francisco General Hospital?
San Francisco General Hospital is a medical facility located in San Francisco, California. This center is recognized for care of Human Immunodeficiency Virus Infection, HIV/AIDS, Cancer, Infections, Breast Cancer and other specialties. San Francisco General Hospital is involved with conducting 258 clinical trials across 327 conditions. There are 46 research doctors associated with this hospital, such as Hope Rugo, MD, Steven J Deeks, MD, Chia-Ching (Jackie) Wang, and Lee-may Chen, MD.